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Historically, the literature investigating conflict of interest has primarily focused on publications tied to the pharmaceutical industry. This is not surprising, in view of the vast sums of money required to develop and test a new drug before it can be marketed. Orthopaedic surgeons have only recently been drawn to this topic.
One of the first examples, "Association Between Funding Source and Study Outcome in Orthopaedic Research" by Leopold et al, 8 examined all articles published in the Journal of Bone and Joint Surgery (American), the Journal of Arthroplasty, and the American Journal of Sports Medicine from mid-1999 to mid-2000. The principal finding was that 78.9% of commercially funded studies concluded with a positive outcome compared with 63.3% of studies whose funding was entirely noncommercial. Interestingly, Leopold et al were unable to evaluate whether this finding applied specifically to the AJSM because only 8 (of 92) articles from that year acknowledged industry funding.
A more recent study of 527 articles published in Spine by Shah et al 11 had similar, although more lopsided, findings. The 84 articles that declared industry support had positive outcomes 73% of the time, compared with 44% of the articles with other sources of financing. The increased likelihood of industry-sponsored research yielding positive findings has been frequently noted in the general medical literature. 1 Although it is common to assume that this association is the result of bias in the design, implementation, interpretation, or publication of these experimental studies, apologists have noted that a company is likely to sponsor research of a product that has already proved promising in in-house pilot studies, thus increasing the chance of positive results in the clinical trial. 5 This topic was again revisited by Okike et al 9 in a study of abstracts of presentations given at the 2001 and 2002 annual meetings of the American Academy of Orthopaedic Surgeons. In this series, a conflict of interest was reported in 40.8% of the abstracts examined. Looking at specific types of commercial relationships, Okike et al found that these relationships only correlated with positive study outcome when they took the form of royalties or stock options or the presence of authors who were industry consultants or employees. In contrast, the provision of research funds or institutional grants by industry did not correlate with study outcome. This finding seems to support the assertion of Brockway and Furcht 3 that "equity poses greater conflict of interest challenges because it has a greater potential for financial gain than other forms of compensation, such as fees or research grants."
In the current issue of the AJSM, Lubowitz et al report a more focused meta-analysis, "The Relationship Between the Outcome of Studies of Autologous Chondrocyte Implantation and the Presence of Commercial Funding." Using the MED-LINE database, the authors were able to find 23 Englishlanguage studies reporting the clinical results of autologous chondrocyte implantation for repairing articular cartilage defects in the human knee. Their analysis was designed to detect any relationship between commercial funding and the outcome of these studies rather than to examine the efficacy of the autologous chondrocyte implantation technique. Sixteen of the 23 studies identified some type of affiliation between a commercial entity and 1 or more authors.
Lubowitz and his coauthors each individually reviewed the studies and classified them by funding type, level of evidence, and reported clinical outcome. The commercially funded studies were then compared with the others to determine whether such funding correlated with a higher percentage of positive conclusions. The power of their analysis to detect distinctions between the 2 groups of studies was undoubtedly limited by the plethora of scoring systems used, 6 in addition to the relatively small number of studies that lacked commercial funding. Within these limitations, however, they reported no effect of commercial funding on study outcome, as illustrated quite graphically in their figures.
Although prospective comparative studies can be relatively expensive to perform, Lubowitz et al found, perhaps paradoxically, that commercial funding was associated with a lower level of evidence. Four of the 7 noncommercial studies were classified as level 1 or 2, whereas only 2 of the 16 industry-funded studies fell into these categories. This echoes the results of Shah et al, 11 who found that only 23% of randomized clinical trials in their review were commercially funded.
In the past, the nature of clinical sports medicine research may have insulated our field from the concerns of conflict of interest. When Okike et al 9 ranked the 13 orthopaedic subspecialty fields according to the prevalence of the types of commercial relationships that correlated with a positive outcome, sports medicine ranked tenth. Only 9% of the 92 AJSM articles from 1999 to 2000 reviewed by Leopold et al 8 declared an industrial relationship. An informal review of the 2006 AJSM reveals that this had only increased to 12% of the 187 full-length articles published last year, despite the adoption of a more extensive conflict of interest declaration for authors in the interim.
It may be symbolic that Lubowitz and several of his coauthors declared a potential conflict of interest. As sports medicine continues to delve into expensive biological technology to enhance natural healing, it is likely that the prevalence of commercial associations with research will increase. Although the only motivation behind scientific inquiry should be a desire to uncover the truth, this discovery process is always susceptible to personal, academic, philosophical, and political as well as financial competing interests. The subtle effects of the nonfinancial influences, in fact, may be more difficult to identify. All research, therefore, should be analyzed carefully for any signs of bias. We should not assume that commercially funded research is universally tainted, but we should also recognize that the potential for financial gain can be a powerful corrupting influence. We can trust, but we also need to verify.
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